<SEC-DOCUMENT>0001193125-14-300988.txt : 20140807
<SEC-HEADER>0001193125-14-300988.hdr.sgml : 20140807
<ACCEPTANCE-DATETIME>20140807172034
ACCESSION NUMBER:		0001193125-14-300988
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140807
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140807
DATE AS OF CHANGE:		20140807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		141024873

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d771994d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;7, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-31791</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3562325</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678)&nbsp;620-3186 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2 &#150; FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;7, 2014, Galectin Therapeutics Inc. (&#147;Galectin Therapeutics&#148;) issued a press release announcing its results of
operations and financial condition for the quarter ended June&nbsp;30, 2014. Galectin hereby incorporates by reference herein the information set forth in its press release dated August&nbsp;7, 2014 (the &#147;Press Release&#148;), a copy of which
is attached hereto as Exhibit&nbsp;99.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for the historical information contained in this report, the statements made by Galectin
Therapeutics are forward looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics&#146;&#146; future financial
performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the
Press Release. For further information on other risk factors, please refer to the &#147;Risk Factors&#148; contained in Galectin Therapeutics&#146; Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2013, as filed with the
Securities and Exchange Commission, and its subsequent filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Item&nbsp;2.02 is being furnished,
not filed, pursuant to Item&nbsp;2.02 of Form 8-K. Accordingly, the information in Item&nbsp;2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement
filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND EXHIBITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Financial Statements of Businesses Acquired. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Pro Forma Financial Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Shell Company Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated August 7, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;7, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jack W. Callicutt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jack W. Callicutt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d771994dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g771994ex99_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Therapeutics Reports Second Quarter 2014 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Norcross, GA (August 7, 2014) &#150; Galectin Therapeutics Inc. (NASDAQ: GALT)</B>, the leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today reported its financial results for the three and six months ended June&nbsp;30, 2014. These results are included in the Company&#146;s Quarterly Report on Form 10-Q, which has been filed with the Securities and
Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We continued to be encouraged by the progress in our development program. We announced on July&nbsp;29, 2014, the results of
the second cohort of patients in our Phase 1 clinical trial for patients with NASH with advanced fibrosis which demonstrated that double the dose of GR-MD-02 that was used in the first cohort was safe and well tolerated. We also have begun
recruitment and enrollment of the third cohort of the Phase 1 clinical trial, that we expect will be concluded such that results may be presented in November 2014,&#148; said Peter G. Traber, M.D., Chief Executive Officer, President and Chief
Medical Officer, Galectin Therapeutics. &#147;This Phase 1 first-in-man study is evaluating the safety, tolerability, pharmacokinetics and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients
with fatty liver disease with advanced fibrosis. Additionally, we recently announced that the first patient has been dosed in cohort 1 of a Phase 1B clinical trial evaluating GR-MD-02 in combination with ipilimumab (Yervoy(R)) in patients with
metastatic melanoma. Preclinical data have shown that GR-MD-02 holds immense potential for increasing the effectiveness of other therapies and may be an important approach in enhancing cancer immunotherapy.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At June&nbsp;30, 2014, the Company had $34.4 million of non-restricted cash and cash equivalents which it believes will be sufficient to fund currently
planned future operations, research and development through mid-2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the quarter ended June&nbsp;30, 2014, the Company reported a net loss
applicable to common stock of $3.7 million, or ($0.17) per share, basic and diluted, compared with a net loss applicable to common stock of $11.6 million or ($0.72) per share, basic and diluted, for quarter ended June&nbsp;30, 2013. There was a
non-cash charge related to modification of certain common stock purchase warrants recorded in the quarter ended June&nbsp;30, 2013 of approximately $8.8 million. Excluding this charge, the increase in net loss applicable to common stock in the
quarter ended June&nbsp;30, 2014 over 2013 is primarily due to increases in clinical trial costs related to our Phase 1 clinical trial, non-cash stock-based compensation expense and legal costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense for the second quarter of 2014 was $1.6 million, compared with $1.3 million for second quarter of 2013. The increase in
research and development expense in the second quarter of 2014 over 2013 primarily relates to increased costs for our Phase 1 clinical trial and non-cash stock based compensation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense for the second quarter of 2014 was $1.8 million, compared with $1.2 million for the second quarter of 2013. The primary
reasons for the increase were non-cash stock-based compensation and legal expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the
Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and
commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains,
in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as
&#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those
described in the statements. These statements include those regarding our plans, expectations and goals regarding clinical trials, including our expectation that clinical data from the third cohort should be available in November 2014, plans
regarding a Phase 2 clinical trial, and plans regarding future funding alternatives and the sufficiency of cash on hand to fund future operations and planned research and development through mid-2016. Factors that could cause our actual performance
to differ materially from those discussed in the forward-looking statements include, among others,&nbsp;that our plans, expectations and goals regarding any clinical trial or any future trials are subject to factors beyond our control and there is
no guarantee that we will avoid delays in the development of our drug products or receive FDA approval for any of our drugs in development. Any current clinical trials and any future trials may not produce positive results in a timely fashion, if at
all, and any necessary changes during the course of a trial could prove time consuming and costly.&nbsp;We may have difficulty in enrolling candidates for testing, which would impact our estimates regarding timing, and we may not be able to achieve
the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues
from any proposed indications. Plans regarding development, approval and marketing of any of our drugs, including GR-MD-02, are subject to change at any time based on the changing needs of our company as determined by management and regulatory
agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional
factors impacting our business, see our Annual Report on Form 10-K for the year ended December&nbsp;31, 2013, and our subsequent filings with the SEC.&nbsp;You should not place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B>Jack Callicutt, Chief Financial Officer,
678-620-3186, <U>ir@galectintherapeutics.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Statements of Operations </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quarter Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center">(in thousands, except per share data)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from equity method investment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock dividends and accretion costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(603</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant modification</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss applicable to common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Balance Sheet Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable, convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g771994ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g771994ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+P#"`P$1``(1`0,1`?_$`+(```$#!0$!`0``````
M``````D`!P@!!08*"P,$`@$!``("`P$!`0````````````$"`P0%!@@)!PH0
M```'`0`!`P(#!0,)"0````$"`P0%!@<("0`1$A,4(14*,4$B(Q:V=SE1,E8W
MM]<8>)A"LR1TM787.#H1``(!`P,#`04$!0P#``````$"`P`1!"$2!3$3!D%1
M82(R%'$C<P="4K(T%?"!D:&Q8G*T=18V",%#4__:``P#`0`"$0,1`#\`W0^W
M.U,,X`YVNW2W04^K$4JHIHM(^)C2(NK/=[9)`J2OTBG1BRS<).QSKA(P)D$Y
M$D$4U7"QTT$55"UUO[JFAU\F63RJ>0"F0G26EZI!^.#"=":-[+C.%9+F.>:U
MT;+Y]*I@]KEKUW2=[K-\H%:?S\8LDY0C(NI`J5!0IE5$S#\/2]-*E#?*=Y!^
M>(1WH>4;@/<\974OS*S8+NE!R7,M2N,&S`SB4:8_KN%4S+*/$7PS8@A'L;#5
MWL=(+>R"CQE\_N"KTTKQ\9'D":^1F@;]L%>K#ZJ9]1>DK7CN<QMAK\C6+T->
MJ%(SY]*&T.#D)*1_+K>WN<[*-UD4OHII(()$^`G*=0XDT(M1+?47-12]+FE"
M,\S>[]H\G\;:CU1R1?<8@`Q.L)V"\5'4LIG+S*62.?62#A#2%2L4?H%<BZ^^
M@FDH=<6[V*DDG8$$/FD(`!I!-2+5)[QP[)H/0W!O)6Y:O+MI_2M7PF@7F[S+
M.*CH-I)6.P0C=_)NFT/$-VD9&H*.%1^***9$R%_``]"345-7U%S2EZ7-*7I<
MTI>ES2J&,4OM\C%+[B`!\A`/<1_``#W_`&B(^ES4U\DA(L(E@]E91ZTC8R-:
M.)"1D7[E%FP8,&:)W#MZ]=N#IMVK1JW3,HHH<Q2$(41$0`/?U5Y`BEW("`7)
M/0`=2?LJ\44DTBPQ*6E8@``7))T``&I).@`ZUA>8:OF>U4]AH.1WVI:52)19
MZVC[72IV.L4$[<QSE1F_;)2,8NX;"X9NDC$4()@.0P?B'[/6+&RX,R(3XKK)
M"3U4W&G6MWE.)Y/A,QN/Y?'EQLU0"4D4HP!%P;'6Q'0TX'K/<UQU+TN:4O2Y
MI0$N?/(9Y#^K=ZUG,<<YQP2/S;)=)ME(LNR7F7T1M7(I&OV!_%LVWT8]Y]:P
MVYZQ:D6&/9``)@<#JG13$IAZ'Q_D7D/*YDN-AX^/V8G*L[;]HL2!>QU8];#^
MH5[,\V_)#\C_`,N/#>-\@\IYWFGYWDL"&>+!QTQ3*YDC5V-V6T<*L2O<DZVL
MH=@11P(^76@XJ+0OUEJ9+&NB7[M9B4:Y%.G(C['"*CIF9E'Y6Y3#\2_-PJ<?
MW^P_AZ[Q#WQ&.^5,OKM!`_F!)/\`77C[.;!;*<\:DJ85_@$CJ[V_O,J(I/V*
M!31[=8NBZG$.K)C-6SS1FC-N9TO598\]%VE=`A/J'-"NVD@K%S"P$`1*@)6Z
MBGN`$^9A`!S`^VM0^ZA9+^5C8VJZS9UDN?MG+=51!PV<O+4@X;KHG%-9!=%5
M8JB*R2A1*8I@`Q3`("'OZFU5W&KS5O*5JL]:*U!.<QSY!M-V&$AW"Z$A8S+H
M(2<FU8K+(E4<?3,LDFN)B@;\!,`>_P"'I8TW5G/07DRU+FJ+UF5N7-"-X_I*
MZ:KG>>QF87&TS,C<+71<_I5ZJXV/\PS1DWJ5?N*M^8QJK\AGR4:Y17.;ZJ92
M^\7-7THPOJ:BN>A^H.VBS]8^;[F_@F6G'@8IEUXY6HDM3!<J!"O[[M,O!6RS
M6EVT$?I'DE,[TEA&D/[>Y$"F`/;Y&]X-6'2NA,T:-6#5LQ9-T6C)DW1:-&K=
M,B+=LU;)E1;MT$DP*1)%%(@%*4``"E``#U0]:BOH]*5%/F#E.L<NR_3+RHRA
M7,1T;TG<>DEX-*)1BFU3GKY5Z7$V:':F0=+DD$7]@J[F4%;X(#]20,G\/X/D
M::4QFR>1VF5'JQGPKA.8VSIKK5.@*:M=,[J$[5Z94LCS<#L$6EFUC2+@^;Q5
M<5F7$NR(PCF;:2DG`.TCB@1-1,YUO;2U8+$^4-E1>KLEXW[`YXO?*FJ=#MI$
M_/%J?7"FZMC6NR\.)"RE.B=`IJ[9W7[NV4<(E+'RL6T!4SA$"*B*Z`*"*58O
M/7_@^=[?W*'_`+6UCU*T]:<_P]'(GXK^!E%#E33)RQDQSG.8"$(0M69F,<YC
M"!2E*4/<1'\`#U!I5EIWD=F>C)'1%^%N:+9U7F^6VZ7SVQ[<KI-#QO)K1?:Z
M($LE8R*<N)W\MIHUUP8&[N408-8$'0_32?*B4PEFPI:G4XF\@F.]N)ZQ6JO#
M7++-QY[N2N>]!\]:HRC8K3LHMB1G":(2"4/)3$%8:Q,&9K#'3$:[<L7I$C"!
MBF#X>H(M2UJL>T>0RD4KH$G(&&9O=NJNKV]82O%MR;+WU:AH3(:2Y.V)'VG<
M=/N,I$T[-F4T=VF$>R.H\F7_`,R&19'3.4X@*4V=:\I%=K'7.6<.=:8?<^6>
M@-[KKZS8-]];*AJ^6ZHVBCR:<I`Q&ATI=)2%N3$T4H)H^2C6A3E$GP6,*J(*
M3;V4MZT,OR6^1SHJL^3CQT\91O*FF0N?/^BE=<))M[CD;RZ=,M,YB+=!0,9G
M$.GHC6"JE1:S4A^:*FM4G#/7ID$`%L@"9@5"I]+T6[=NP?Z3YMTB\;AP?V&\
MHZD;;*Q=LN@:ICNEV^2S\U->O[59)%AFVX6**94M2*,X9JJ*2"3[ZH&^+?X>
MR@XI88YXFAE%XG4J1[018C^BL^)E9&#EQ9N&Y3+AD5T8=5=2&5A[P0#4?_"K
MT#RIL/`4GH_%//.A8_B%3T_7(:"S*=EF%FT.VSE=3C9>4F4UW-EDVAY>UJ/T
MD&C9Q)_%,R9"'5(3\0UN/X[%XO&&)A+M@#$ZDDW/4DFN7\E\FYKR[E6YGGYN
M]R#(J[MJJ`J"R@*H``'V=236`Y+YZ\&T+J/;N3;MSMTQAFJXY6(J28T;2JM6
MW>JZC<IN3B&D1FN=9A0[)<)*:LTO%SK:3;*E=BQ&,%1VLL@U157)O6K@+&LD
MW;S%SW'EJS1]VWPAT!S9SSK%SCJ%7^CE[QC&JUBIV*;*JK#--8J^87&?FZ%]
MTV056.)5'X$206%/ZIDCE!:EK]*-@@NBZ01<ME4UV[A)-=NNB<JJ*R*I`426
M24((D4343,!BB`B`@/X>JTJ!>[V6K<*<V/(_(85E%S%CM<VG`&7127.XNU\E
M)>UVNZS8_3)^:R`+K.7/\SW*97Z*0A](H%#7P<*#!A&/CBR;BQ]I9C<D^\D_
MRM7.^2^3<OY5R9Y;FI3+E=J*)?U4BAC6**-!^BB(H``];DZDF@35NKZQTCH9
MXJ,6D]"T.<2D)916>GFY'3I-BF+EZJ,A-.V[-`B"8^Y4BF(4`_`A?W>MW05U
M[4T1'*<X\E>.5"Q4FH5M%2&FVI4(T9RYT^9<4UP)_P">_J9GE@.1@LX0$Q!2
M."C<IA!0J8'+[C!M4_$*C?(<%]C2[][*RN>_F4G).EWTC(/KY3W+Q\]=*F6<
MNW;A2=,HNX<+'$QS&$1,81'TN*BQJ\TS@KJN)N-1E9#-6R#"+M->DGRP7*G*
MBBS83#-TZ5!-.:,HH*:"1A^)0$P^WL`"/I<4L:V-_B7W$?B7^+W]_P``_'W_
M`&^_^7W]O5+UDK]>KU%<YO\`4'9K:^1_.MC?;,Y#2!LGTJU<I;$VMGVBRD*A
M8,56JM$MU5.\$/MRS+*LY4WDOM_D!Q;N@.`>WN/J#5QTKHJQDG'S4;'S$2\;
MR,5+,6DG&2#-4J[1]'OVZ;ID\:K$$2+-W394IR&`1`Q3`(>J&JT.'R:9YN1N
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M;+(I)_13^H4"_P`PWNN*4$']*Y:'^N3?E7WO072DMMVE=:1+B_2DF`*S2+(6
MEPEHR,464]UT6+.3E'R"2(?$B96Q2```F4`'I4FMJVQ97F5NM])T&UYY2;+>
M\U5E5\\N<]5H26M5%6G6@,9I6HS[]DO*UT\LS*"3D6BJ0K$``/[@`>H%16L!
MY7/_`-#'@S_\OH'_`*A.^I'2I]*V<=I(53'-93.4#D/F=\(<A@]RF*:K2H&*
M8/W@8!]A]0*BM=[])?\`X3P?\SNW_P#=T[U)Z4/6FVY6BXM]^JR\B,@]C8]X
M_A>1*`YAGSMFW</(AR\K'/4<[<Q;E9,ZS!PZCEU&ZBB0D.=!0R8B)#"`R:>E
M//\`JN6R*_B+MZBH?S&>]88Z:_Q`40<?U"^;^X!^TW\AP?\``/Q_?^[U44'6
MC[8(<ZF%XNHH<RBBF39R<YSF$QSG-3X<QCF,/N)C&,/N(C^T?0]:'K42^]J`
MMO/.C.U9FY0MYZ7.?U@T)`+DDR34*U0D86QIQPM15!T]C/F90R1?=0#-E$_;
MZG\/J5TTJ&!M0/\`#-GL."Z$PTBK1D-,2\?'RT8FQGBO31QDI9L+1P94K!RT
M=`LB7_-`#@`&_:`_L]7ZUC!M19^8>W>ANB-4B*6AG>?-:PU$TC>+#'MK0(P,
M$B0X^Z:[B:6:$DY)P!4&R9RF$QSB;XB4AA"I`M5P2:*I+NSL8J4?(@0RK&/>
M.TRG]_@91LV47(13XB!OB82A[^P@/L/K$]PI(Z@$ULXL:S9,<+?*[JI^PD"M
M1.@_J$^L;9HU'IS['.?FT?9[Y5ZL]<M&NA`\08S=C8PSEPU%:XJ(@Z2;NC&)
M\BF)\P#W`0_#U^4Q>=\N\RQF/'VLX'RMZD#]:OIGS/\`TE_+;C>"R^4AY3FV
MGQ\.:90S8VTM'$S@&T`-B0`;&]JV_?7ZQ7S%JOK)45$#N/A[`?(1S[:.<NB:
MVK-5"=.C*0DY%*I,;=0K<P37)#76ES"B#C\KGXH7"A0$R:B#ENJJW7350543
M-4G6I&E#CY(S'RN^.JFPO-4Q4LZ\D'-E!;!`XMJ4)J$1A'3-)H;`00@*5HE3
MTI!7.[VWKT<F5NQ=L["U<)-P(D?ZA"$*FZTTIPNNZ9Y*>\<3OO,]"R_..%L_
MURO/J5J&RZQID1L^K$H%@;E8VBOYKF&/_<U%I-3L4LNR5D96U$(@W64^DA]4
M2*D=*:5G_B-\6E<\3V#WK$*WLMCVQ&^Z:OIS^QV*IQ%.4CI!S5*U5U8F/BXB
M2E4QCBDKA5B&56.J`JB41$``?4$T)O0TTN!/(]QWYG.C/(1SCF61]>XSUO5%
M:W:J]>=I;XUH&6M7AJ2Z3C6<G-UBSMW,=7)6C(%:_9HNRN(E;Z)D4ETB&]3U
MJ;Z6J\>3+QY^3?J'0.'NOZU+X7H.K<A="1.HQG(5?GU:%G4;4@EJM.2241N5
MPA?S^ZWY^YIS9N_>OV4-%E;G+]E'IG24.Z5%ZD3WCC7E$["\?VN\T%QWGYII
M743:;2GUI+=%HVK\WT=6WPCZNYNW>1>7.WNRVA"N00J/IH"Q33\Q?JD33.W0
M2$\WII>GPX!Y=W6)\?4#X_\`NW%<Q;U*H8*VP"4G\^UQWH,/J]3=Q4K6Y%56
M'?T>J2E)?H02B`_+[AX`.3"=$Q/@4`BGOJ+'!?.W?GB'K%JY,K6)CWCQXVO%
MEN//&BT#4<ZSC;\OB+?(JRDGG.GT/6)FHUF>8(RZBCQ&6AI8_P#/=+F.V*50
MB:"U";T5O$&/55XTN4V'>T(O%J0C4%*EGG,-7M4;?G35Z_E&4E-Z;L-^C8ME
M$2EU42C$F,1$0JCB*B&*KDZCM\X=`+4=*4(JN^/+J[QH=Y[MUOX^J)5.B>8^
MP'(3G0_(4Q?H?)]`HM_2DY2=)?,3MMG3+0IIBE+S<BH2)DUX\4T))9J1003;
MJINM3>]$RBK)V3T98*-&S.+S_&.3P%KK]RT*8LNIT"W[+HK*L2"4PRS&J0^3
M2]LKE1JUEEF2*=@E7TS]XXA_K,6[,!=F<H-!45`7RY<&]2ZIU5P!Y"..JG3M
M=U3B>Y30VC![?<F6=*:30K$[9O'(5>ZRZ:D#&SD<F5\C]-X*93?>)J$$XI&2
M4"E_2ID66]>2'0,/TUZGR7C57N&B0KZF9[C=GZ+;EF,Z8R%2FF4I>-6TJM4R
MU5.RN9*P/VY6T#`-!!FR;&.I)+*N!3;-*5!_P:\>=[^-CF>R<L;IC^*6>%;V
MW2]7J>C9YO#URXDK#8XF&-'4.;JDQF;(T>E(2\0*82R3Q5-LBJ`G;'$G\0T-
M,W@_&OE*S7R_=`>2RR\^\TNZ-T3GL-DLIE$1TW,&M='K$,USF/C;$VLSK&TX
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M]C$6&X_8*B!OM8U%RJ[*'P%VW*(*!%2!1`O`;N>J]+^+9EO&VVY_>=1T[4.E
MK-;K&_\`BG]R^=:%9$D6<>R3_P##1,)$LD4FC%DB!4&C1%-(@`4@>J2?(?\`
M"?[*VL']_A_%3]H5IYXQ_KTR3^^+/O[=0_KSGC_O4?XJ_M"OOOY5_P`0Y/\`
MTO)_R[UTYO7HT]:_G]JOK)453U0]:4O45-+TI2]*4O2E+TI2]*4T&H9-4M!=
M15CM))A^>EP-O2AX=O/S,7!+/+"VC/K2DI&Q+UD26D8Y&'!-D=<3E;%<K"0H
M'.!BZ.;APY0WS7(16L`2!<@:FQ%R+:?::YOB.8S.-#8V)L7OR1[F**S`(3\*
ME@=H;==K==HOII4&_&QF<+:>0^6MDG)2XR-]E\2E8RU2CZYVA]_6B-K=%*^=
M6A-[*N/S*5:#$)&9O/<CIK\U`34*50P#PW`X,+\9C9IW]]H"&^)CNW==USU%
MM#U%=X_,?ELC&\MY3A85A7`3.5HP(XQVNWT"6464[CN75387&E87QMU7-9[S
M[@U?V"#?NX1URAJ^Y1^@EN,E=;7(P>$34*WN#:V,)6-0=A+R<-;6;J/4)(/C
MJ?2527$B@%$VOPW*R8^!CQ9B_=G%>0.&+,1$?BW`@6)!!74^PUO^:>)X_(^0
MY^3PTBC(7EH,5HNVL48?*5NV8RK$;59&#W1.H*W%/5(]J:3#<]Z#T+*<US;>
MN5G+:#KU3;NKQ$1S>YPMS`[F4J2,@I&NG#&XU&-,W744,T-$O_O$BHNBB542
M;G\;RQQ\F>V*P18T=;M8,&_1O;YET]-IOH17")X1Q4OD6/X]%RB'(ER98)"(
MBQC:+I(1N`,<AN`-W<3:=RFXO?MKZTT+!*(YMM^R6I(R\-3]'T*7IT%J:MEG
MI&L4)^R430J\=&4<)9TYD*T[.[>R3QHS@X=RD1LX=F%RDIZMG<QE<?`)<F&,
M.%9BHD+$JI'R@+?H;EF`1;6)U%8.#\/XWR#/^DX_,F,+S0Q+(T`10\H.LA:7
M:`'&U45FED!+*GPD534>M]!HMOWJ'@L;@[)6\`PBD]$3LR\THT),V6EV9/1%
M92OPT$:G/6;"W12.:2)T0=/P8N0^D4RR(JC]/)E<ME8\TR)"C100+,27()0[
MK@#:1N&TVN;'VZU7BO$>,S\/`FR,V6+*S\^3#11#N5)4[6UV;N`F-N\@.U=P
MULIMK]E?[(?Z+H[^I9#CMLT"LU5]B36\V<CUA!NH9GM]1B;ZSF6D9*"BW<,J
M-3+#'/Y5-5RDY<%<*)-"*K-Q(K5.;;(RNSAP/)"O;WMT([BA@;'2RJ06N;G6
MW2HR/"HN.XL9G,9L./ERC),4=BP8XTC1%21K>61'6,A2!8%R`UQ[U?KV4GK#
M3X)WF3=@6P=8:URI+/$+J5Z,5+YK4;G<&-S8-E*VS/+Q5A:4I=%1H8S99BHL
M0?FL4#>LL'*RRR+&T2K?*D@/Q7L44L&`VBX(!TTM[ZQYGA\&-C2Y"93-LXG'
MSE!BMN6:2.,QD[SM9#("&^(.`=%IJD>A;A<Z'0;9J.<1#ALMWN;$*^G0M3M]
M:5A5*MNEMRFNVN8*T@XPUM8LGT$FJ\AW"OV,FDJ852E`@)#I)GY&1`DF5&FW
MZ_MKL=A;:[*";`;@"-039O7V5R[^.X.#G9&+Q63('_V_]2_=@C<-W,:.9T6[
MMVR0WPR`;D(T)O>G^I/1=QTI6[62A92%BS2DWO9<R=2)+<T8WF2M6,J3$-).
M(VI.XPL>M%62^0:\(Q(:1(Z*/TWBI"H*"4G(0\CD9!>6"$-B(\B7W6<M'<&R
MD6LS`J-;]&.E=>SO&\'C!!BY^7V^4G@QY@.V3$L>3M8`R!K[DB82N=FWJ@)8
M7.2\P]!->C:')W%&,803N&LKBK3%>2>S(SE>FF43#R,K`7&NV:N5.STVUP;Z
M449NH]\R*8WVY7**BK9PB<<G$\B>2@,Q4*ROM(!-P;`D,"%92";$$>EQ<$5K
M>5>.GQK/3#WM(CQ"17(7:ZEF56C='D21&"AE=6]=K`,K"N/=VU_]S^N_^9_?
M/]JEJ]<M77!TJ,7I2J^E*ZA'Z9;_``5\R_\`=W1?^T*S^L<GR'_"?[*V<']_
MA_%3]H5JFXQ_KTR3^^+/O[=0_KSGC_O4?XJ_M"OOMY5_Q#D_]+R?\N]=.;UZ
M-/6OY_:KZR5%4]5(UI2]1:E+TM2EZ6I2]+4I>EJ4O2U*L%JB86=K<U$6)=9M
M`R$<Y;RZ[>8?5]5...F(NS!-1CR/?QI/H@/S5272,4GO_$`>_K%-%'+$T<IM
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M`L0RZC<=0-+G05RW(\OYUDC,BY!,D-+EPG)OC!&&2`1!O81*T<M@W;4%2?C(
M!NQK[7F5<:)8;-04O,4A7GV<S^O*O%I?8)$^?M<C2=?<U5*'L;FY@P@<S!PH
M`,@9ND(U0GQ3*)DRD($_1<(,1D+)]$R+>\IV[+_#8[M$OTL0#6->7\U;G$GB
M2<<_'D.`%QE[IR"+2%D$5WFM\VY2XU)L237KM^<<76*:%?>Y+-&\[#X;:(:2
M+==34J[Y?GI]*1*%J5M;=>W1!YS."3Z3(7#^3*NT;R'TC?6(N8!&<[$X61P>
M0:/N+"1\4A4]JXON^(76]M6N-WK>J\'R?FV-#;Q]<DP/G(P[4`<#+"L4[9$;
M;)MFZR)9BEQ8K3!26&XFZWC:;#J-LQX,!1Y6Q"JJ0#CH>SH6)KG-)LVJR;J?
MV6`=!#Q+O*;8K8UVR;Z6G)1L]-#.`6^8++II:#<?@MG2ODO#_#ABHH'?;=L5
MF),@T!0W(NSL#M/M-NP1\]SB<#AX_%PYG^X3RN3)N&'&4,TB0J$QG&YA.@0,
M5CBC*B1;6VJ3+8:5SA*Z1.V=A(4]#0(QAF:-V95N]#$&<,$%EW..FO\`5(*>
M:1TDF"BI_P"GE)-H<5D_Y;<3IE*4.5;'XM\@RDQ_4`)NL]OP]Z@@'^YN&O0:
M5U)<[R:'C4Q668\>[3=LO%NL2+9':D="RG_[;&%CJUB;TW:V6<4NM/A+2:7S
MXNDGWB?G:NS:Z^]9KDZ,CJV[0NZ-=J#.YH1A=(7J8+_G\<W9_<N&8*'>H&*)
MS#@^CX1LH2[H_JN^Q%I2/O0/CLH:V^WS@"Y'46KD%Y;S=.+?$V9'\,^@17)Q
MP1](7^Z+R&,MV0]NTY:P:P1@;5[2&4<9R,691S+TI*"?=%I6QL#+9):+@TNF
M$+K*%(TB$HZ[-(YCH`Z3]\)X5L!#J3HK_-J9R!P`V%PKB^Y`IR-VDI`[VX]+
M-8-NO\(_2OI>D?+^:Q2;52<S+QO;UQE9OHNVNK%HB3%V=OWAN!%MLVVU90SS
M[EM9WIE@C).G`RF[5=V6I,HG27"%00T1>KN(W1%Y^O1]F3K<!H850%1EEOH-
MI)-+YN%A*?Y*^LAQ>'+2R7CLS,'M)9=^TA[J&VA]M]V@(%R?;6JW)>6JF+CR
M)/O2*(P%H`9#")`T(1RF]X>Y;MB[(391<6%.5E]9RFJJ7".S5Y%/9)2:AW-]
M60M3BW6$)H]-K:5:3M4E(RLO,IN4\^1B`8)NE`'\J^V.F`IG*<VUAPX<.]<,
MJ6W#=\18WVC;N))/R[;7]+&N+Y;+Y?+$,G**ZQA&$5XQ&FWN.7V*JJMNZ9-Y
M4?/N!U%@`O2^7OTL\IH^@2>JV;QB):C(W>UO])2M/7V>P]G3OSN=?N+@2QQ#
MG:V+B*GB6%1P#QLHBB=!Q\R&(02B4-ZN(UK"/^%#])5_I3XIO^L_-_\`?KZ4
MU]]+_A0_25?Z4^*;_K/S?_?KZ4U]]&_XKI/$5&YLA:OP>]Q=[RR@_N"D"YPR
M_P`3HF8&D7LL]6NP,;A#V2SQ[AP294<`]*5Z86ZWR*8""`@%6`(.ZVVVO_FL
MD+2K,K0W[P8;;"YW7TL/4WZ5`NMX#X$VMIK[RK3O#QK<VL40ZK9(SI6KO)4U
MG0E&ZT,6/8DU1=1W)&ERI`BB"9S**^Q0*(C[#TU.-\'#@HV)W`PM]_ZWT_\`
M9[:]8YWFO_<N3CIHN0A\N_AC0.)=W%2JG:*$/N;Z,!5V7W-<6%S<=:-OZ[E:
(O)-5]7I7_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
